
A new clinic in Suffern is offering an FDA-approved nasal spray treatment for people whose depression hasn't improved with standard antidepressants, giving Rockland County residents another option close to home. Marpa Minds, which opened the location in August 2026, treats patients with Spravato, TMS and ketamine therapy out of its Rockland County office.
The clinic lists its address as 10 Executive Boulevard, Suite 104, in Suffern, according to Marpa Minds. Spravato, the brand name for esketamine, is a nasal spray that's FDA-approved for adults with treatment-resistant depression, and it's aimed at people who haven't found success with other antidepressants, as reported by News 12 Hudson Valley. Marpa Minds also operates a location in White Plains, per the same News 12 report by reporter Diane Caruso.
What a Treatment Session Looks Like
A patient identified as Raizel, who has received Spravato treatment for the past year, demonstrated a typical session for News 12 using a tester nasal spray. She said the treatment made a significant difference in her life and helped her process things in a new way, according to the station's report.
Each visit runs about two hours, including a required monitoring period and time in the clinic's recovery lounge, the clinic's website notes. Patients remain at the clinic for a couple of hours after taking the medication while providers monitor them, and they need a ride home afterward since they can't drive the same day. A typical treatment plan starts at twice a week for the first month, then tapers to weekly and less frequent sessions as the patient stabilizes.
Clinical Director Weighs In on Safety and Results
Amy Della Rocca, PMHNP-BC, serves as Marpa Minds' clinical director and is described in the News 12 report as a psychiatrist with the practice. She said esketamine has produced results unlike those she's seen with other depression treatments, and she said safety remains the primary focus in the clinical setting, since Spravato can cause sedation and dissociation as serious side effects.
Those risks align with the drug's federal labeling: the U.S. Food and Drug Administration label for Spravato calls for monitoring patients for at least two hours after administration and identifies sedation, dissociation and respiratory depression as risks following each dose.
What the Research Shows
A double-blind study published in JAMA Psychiatry in 2025 found that esketamine reduced depression symptoms, according to the study cited by News 12. Patients receiving esketamine showed improvement after 24 hours and again at 28 days, and that improvement was greater than what patients receiving a placebo experienced, per the study.
A separate 2023 study cited by the same outlet found esketamine was associated with a 54% increased likelihood of patients reaching remission for treatment-resistant depression at eight weeks compared with quetiapine.
A Second Rockland County Clinic and a Growing Patient Base
A September press release described the Suffern location as Marpa Minds' second clinic, promoting it as bringing “15,000+ Spravato Sessions of Experience” to Rockland County, according to the OpenPR press release. The clinic's own website separately reports more than 13,000 Spravato and ketamine treatments given, a figure that uses different wording and scope than the press release's count.
The Suffern location adds a local option for Rockland County residents seeking treatment for depression that hasn't responded to more conventional approaches.









